No pain, no gain: Ozempic’s quest for market share
Update: 2025-09-11
Description
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
